---
title: "Whole-genome sequencing identifies rare coding variants and key genes associated with acute myeloi"
id: "medrxiv-21-prioritizing-genes-and-rare-protein-coding-variants-in-acute-myeloid-leukemia"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-21-prioritizing-genes-and-rare-protein-coding-variants-in-acute-myeloid-leukemia"
content_type: "clinical_feed_article"
specialty: "Hematology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.19.26360760v1?rss=1"
published_at: "2026-08-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Whole-genome sequencing identifies rare coding variants and key genes associated with acute myeloi
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-21-prioritizing-genes-and-rare-protein-coding-variants-in-acute-myeloid-leukemia
- **Specialty:** [Hematology](https://medichelpline.com/clinical-feed/hematology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.19.26360760v1?rss=1)
- **Published At:** 2026-08-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This preprint analyzes whole-genome sequencing from the All of Us Research Program to evaluate the contribution of **rare protein-coding variants** and common variants to risk of **acute myeloid leukemia (AML)**. - The study used a European-like ancestry sample with Ncases = 265 AML cases and Ncontrols = 169,706 controls for association testing. - Rare-variant set-based tests were performed with **SAIGE-GENE+**; single-variant tests were performed for common variants. - Four genes reached statistical significance in rare-variant tests after Bonferroni correction: **DNMT3A**, **TET2**, **SRSF2**, and **IDH2**. - The authors constructed rare-variant burden risk scores across multiple gene-sets to identify aggregated rare-variant effects linked to AML. - Gene-sets derived from Genomic Data Commons (GDC) whole-genome sequencing—one comprising genes with somatic mutations observed in AML and another with genes mutated across cancers—showed a statistically significant rare-variant burden after multiple-testing correction. - The data sources and tools used include the AoU Curated Data Repository (version 8), VEP v115 for annotation, GDC clinical and RNA-seq data, single-cell RNA-seq (GSE116256), and ClinVar; code and summary statistics are provided on GitHub subject to AoU reporting limits. - The study is a preprint (not peer reviewed); authors state no competing interests and report standard ethical approvals for use of All of Us data. - Details such as effect sizes, per-variant p-values for the significant genes, and replication in external cohorts were not reported in the abstract and must be consulted in the full manuscript or supplementary material.
## Clinical Analysis & Structured Key Points
Prioritizing Genes and Rare Protein-Coding Variants in Acute Myeloid Leukemia via Whole Genome Sequencing Data | medRxiv Skip to main content Prioritizing Genes and Rare Protein-Coding Variants in Acute Myeloid Leukemia via Whole Genome Sequencing Data View ORCID Profile Stephen Vieno , View ORCID Profile Madhurbain Singh , Sydney Kramer , Chris Chatzinakos , Roseann Peterson , Brien Riley , Silviu-Alin Bacanu , Thang Dinh , Bon Q. Trinh , Tan-Hoang Nguyen doi: https://doi.org/10.64898/2026.08.19.26360760 Stephen Vieno 1 Virginia Commonwealth University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Stephen Vieno For correspondence: stephenevieno{at}gmail.com Madhurbain Singh 2 King's College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Madhurbain Singh Sydney Kramer 1 Virginia Commonwealth University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Chris Chatzinakos 3 Downstate Health Science University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Roseann Peterson 3 Downstate Health Science University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Brien Riley 1 Virginia Commonwealth University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Silviu-Alin Bacanu 1 Virginia Commonwealth University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Thang Dinh 1 Virginia Commonwealth University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bon Q. Trinh 4 University of Virginia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tan-Hoang Nguyen 1 Virginia Commonwealth University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract The extent to which rare and common genetic variants jointly contribute to the risk of acute myeloid leukemia (AML) still remains relatively unexplored in large-scale biobank whole-genome sequencing cohorts. Here, we leverage the latest sequencing and phenotypic data from the All of Us Research Program to identify variants, genes, and gene-sets associated with AML. We performed set-based association tests for rare protein-coding variants (Ncases=265 and Ncontrols=169,706) and single-variant association tests for common variants (Ncases=265 and Ncontrols=169,705) utilizing the large European-like ancestry sample. For the rare-variant set-based tests conducted using SAIGE-GENE+, four genes were statistically significant: DNMT3A, TET2, SRSF2, and IDH2 (Bonferroni-corrected Cauchy p-value < 0.05). We also constructed multiple rare-variant burden risk scores using different gene-sets to identify those with a substantial rare-variant burden for AML. Gene-sets derived from Genomic Data Commons whole-genome sequencing data, comprising two distinct groups-genes observed to harbor somatic mutations in AML and genes observed to harbor somatic mutations across all cancer types-showed a statistically significant rare-variant burden (Bonferroni-corrected p-value < 0.05). Ultimately, these findings demonstrate that leveraging whole-genome sequencing in large-scale biobanks enables the identification of rare protein-coding variants, genes, and gene sets associated with AML. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The data used in this study are publicly available. Individual-level data from the AoU Curated Data Repository version 8 [https://www.researchallofus.org] were accessed following approval of the Data Use and Registration Agreement. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data used in this study are publicly available. Individual-level data from the AoU Curated Data Repository version 8 [https://www.researchallofus.org] were accessed following approval of the Data Use and Registration Agreement. VEP version 115, along with associated annotation plugins, was used to annotate variants present in the AoU dataset [https://github.com/Ensembl/ensembl-vep/archive/release/115.zip]. Clinical information, somatic mutation frequencies, and RNA-sequencing (RNA-seq) expression data were obtained from the Genomic Data Commons (September 18, 2025 - December 1, 2025) [https://portal.gdc.cancer.gov]. Single-cell RNA-sequencing data (GSE116256) were obtained from the Gene Expression Omnibus on December 10, 2025 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116256]. Variants present in Clinvar were obtained on April 12, 2026 [https://www.ncbi.nlm.nih.gov/clinvar/]. The AoU does not permit the public sharing of AoU workspaces; however, to facilitate reproducibility, all code implemented within the AoU during this research is available in the accompanying GitHub repository, along with the corresponding summary statistics [https://github.com/StephenVieno/Rare-Variant-Analysis-of-EHR-Derived-AML-in-the-AoU.git]. In accordance with AoU publication policies, participant counts below 20 and allele counts below 40 are not reported in the publicly available summary statistics. https://www.researchallofus.org https://github.com/Ensembl/ensembl-vep/archive/release/115.zip https://portal.gdc.cancer.gov https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116256 https://www.ncbi.nlm.nih.gov/clinvar/ https://github.com/StephenVieno/Rare-Variant-Analysis-of-EHR-Derived-AML-in-the-AoU.git Funder Information Declared National Institutes of Health , R21MH137508 , K25AA030072 , P50-AA022537 National Alliance for Research on Schizophrenia and Depression , Young Investigator Grant 28599 National Cancer Institute , R21 CA270067 , K01 CA222707 American Cancer Society UVA Comprehensive Cancer Center UVA School of Medicine Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted August 22, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Prioritizing Genes and Rare Protein-Coding Variants in Acute Myeloid Leukemia via Whole Genome Sequencing Data Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Prioritizing Genes and Rare Protein-Coding Variants in Acute Myeloid Leukemia via Whole Genome Sequencing Data Stephen Vieno , Madhurbain Singh , Sydney Kramer , Chris Chatzinakos , Roseann Peterson , Brien Riley , Silviu-Alin Bacanu , Thang Dinh , Bon Q. Trinh , Tan-Hoang Nguyen medRxiv 2026.08.19.26360760; doi: https://doi.org/10.64898/2026.08.19.26360760 Share This Article: Copy Citation Tools Prioritizing Genes and Rare Protein-Coding Variants in Acute Myeloid Leukemia via Whole Genome Sequencing Data Stephen Vieno , Madhurbain Singh , Sydney Kramer , Chris Chatzinakos , Roseann Peterson , Brien Riley , Silviu-Alin Bacanu , Thang Dinh , Bon Q. Trinh , Tan-Hoang Nguyen medRxiv 2026.08.19.26360760; doi: https://doi.org/10.64898/2026.08.19.26360760 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (609) Allergy and Immunology (891) Anesthesia (324) Cardiovascular Medicine (4736) Dentistry and Oral Medicine (473) Dermatology (404) Emergency Medicine (637) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1608) Epidemiology (15764) Forensic Medicine (32) Gastroenterology (1193) Genetic and Genomic Medicine (6943) Geriatric Medicine (723) Health Economics (1049) Health Informatics (4938) Health Policy (1418) Health Systems and Quality Improvement (1729) Hematology (574) HIV/AIDS (1323) Infectious Diseases (except HIV/AIDS) (16217) Intensive Care and Critical Care Medicine (1155) Medical Education (657) Medical Ethics (150) Nephrology (715) Neurology (7133) Nursing (359) Nutrition (1067) Obstetrics and Gynecology (1218) Occupational and Environmental Health (992) Oncology (3557) Ophthalmology (1030) Orthopedics (387) Otolaryngology (442) Pain Medicine (463) Palliative Medicine (138) Pathology (702) Pediatrics (1764) Pharmacology and Therapeutics (730) Primary Care Research (756) Psychiatry and Clinical Psychology (5795) Public and Global Health (9641) Radiology and Imaging (2364) Rehabilitation Medicine and Physical Therapy (1421) Respiratory Medicine (1234) Rheumatology (631) Sexual and Reproductive Health (761) Sports Medicine (571) Surgery (756) Toxicology (106) Transplantation (300) Urology (285)
## Related Clinical Research

- [2026 Stroke Rehabilitation Guideline: Start Early and Address Physical, Cognitive, and Mental Heal](https://medichelpline.com/clinical-feed/medical-news-today-0-stroke-rehab-guidelines-emphasize-early-support-for-physical-cognitive-and.md)
- [How pre-vaccination immunity heterogeneity drives variability in vaccine effectiveness estimates](https://medichelpline.com/clinical-feed/medrxiv-5-heterogeneity-in-pre-vaccination-population-immunity-can-contribute-to.md)
- [Diet and Alzheimer’s risk: Why no single best diet fits everyone](https://medichelpline.com/clinical-feed/medical-news-today-0-is-there-a-best-diet-to-help-lower-alzheimer-s-risk.md)
- [Polygenic and familial influences on antidepressant continuation, switching, discontinuation and a](https://medichelpline.com/clinical-feed/medrxiv-13-polygenic-and-familial-contributions-to-antidepressant-continuation-switching.md)
- [North West London Diabetes Cohort: multiethnic EHR resource for diabetes complications research](https://medichelpline.com/clinical-feed/bmj-open-2-large-scale-multiethnic-electronic-health-record-resource-for-diabetes.md)

## Navigation
- [← Back to Hematology Feed](https://medichelpline.com/clinical-feed/hematology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.